![]() Aetna considers NIPT not medically necessary for pregnant women who have previously had a multiple serum marker screening test with or without fetal nuchal translucency ultrasound that is negative for fetal aneuploidy during the current pregnancy.Aetna considers non-invasive prenatal testing (NIPT) using measurement of cell-free fetal nucleic acids in maternal blood (e.g., ClariTest Core (chr 21, 18,13, X,Y), MaterniT21 PLUS Core (chr21, 18, 13) NO Gender, MaterniT21 PLUS Core (chr21, 18, 13, X, Y), Panorama Prenatal Test (chr21, 18, 13, X, Y only), QNatal Advanced (21, 18, 13, X and Y), Verifi Prenatal Test) medically necessary for screening for fetal aneuploidy (trisomy 13, 18 and 21) in all pregnant women.Multiple serum marker testing is considered medically necessary for women who decline these more invasive procedures. Preventive Services Task Force and the American College of Obstetricians and Gynecologists, women aged 35 and older who desire information of their risk of having a Down syndrome fetus should have chorionic villus sampling (CVS) or amniocentesis for detection. This Clinical Policy Bulletin addresses serum and urine marker screening for fetal aneuploidy.Īetna considers multiple serum marker testing (dimeric inhibin A, human chorionic gonadotropin (hCG) with maternal serum alpha-fetoprotein (MSAFP), and unconjugated estriol) medically necessary for pregnant women who have been adequately counseled and who desire information on their risk of having a Down syndrome fetus.Īccording to recommendations of the U.S. Number: 0464 Table Of Contents Policy Applicable CPT / HCPCS / ICD-10 Codes Background References
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |